BioCardia, Inc, a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, with clinical programs in heart failure and sub-acute infarction, announced the issuance of United States Patent No. 9,517,199 relating to a method of delivering cells to patients who have chronic myocardial infarcts.
This new patent follows United States Patent No. 9,504,642, issued to BioCardia two weeks ago.
Dr. Peter Altman, CEO of BioCardia said “We are pleased to have obtained this additional new patent which provides further protection around our CardiAMP program.
Our patent strategy is to pursue protection around our active programs where we are investing our resources.”
